Evaluation of second trimester abortion methods in a tertiary care centre
DOI:
https://doi.org/10.18203/2320-1770.ijrcog20243595Keywords:
Pregnancy, Abortion, Gestational age, Morbidity, FemaleAbstract
Background: Wishful termination of pregnancy is among the many rights of women’s health care and while the rate of abortions is much more in the first trimester, morbidity and complications increases as the pregnancy advances are much more in the second trimester. We assessed the various methods of second trimester abortion available in a tertiary care centre while evaluating the efficacy and safety profile of these methods.
Methods: We conducted a retrospective cohort study in 50 patients of age group 16-36-year admitted for spontaneous abortion or medical termination of pregnancy (MTP). Demographics, gestational age, parity and indication for abortion was evaluated and appropriate method offered. Induction abortion interval and various complications were noted and managed appropriately.
Results: Fifty patients of age group 16-36-year were included in this study. Majority of them were married and multiparous and presented early in second trimester between 12-16 weeks of gestation. Spontaneous abortion was seen in 14 cases and 9 cases had fetal anomalies requiring abortion. We found the mean abortion induction interval to be 15 hours and 8 min and the most common complication was fever seen in 12% of the patients.
Conclusions: Safe abortion services, particularly in second trimester should be made available to every women and improved policies and monitored services should be rendered for the same to decrease morbidity and mortality associated with it and give overall better outcome for the patient.
Metrics
References
Shah I, Ahman E. Unsafe abortion: global and regional incidence, trends, consequences, and challenges. J Obstet Gynaecol. 2009;31(12):1149-58.
Tejal P, Bakul L. A 17-year review of voluntary termination of pregnancy (MTP). J Obstetr Gynecol India. 2006;56(6);522-8.
Drey EA, Foster DG, Jackson RA. Risk factors associated with presenting for abortion in the second trimester. Obstet Gynaecol. 2006;107:128-35.
Grimes DA. The continuing need for late abortions. JAMA. 1998;280:747-50.
Muyuni M, Vwalika B, Ahmed Y. The determinants and outcomes of second trimester abortion at the university teaching hospital. Med J Zambia. 2014;41:1.
World Health Organization, Trends in Maternal Mortality: 1990 to 2010, WHO, UNICEF, UNFPA and the World Bank Estimates, Geneva, Switzerland; 2012.National Cancer Institute. Fact sheet: targeted cancer therapies. 2012.
Medical methods for termination of pregnancy. Report of a WHO Scientific Group. World Health Organ Tech Rep Ser. 1997;871(i-vii):1-110.
Tietze C, Henshaw SK. Induced abortion: a world review. 3rd edition. New York: Alan Guttma-Cher Institute. 1986.
Kafrissen ME, Schulz KF, Grimes DA, Cates W Jr. Midtrimester abortion. Intra-amniotic instillation of hyperosmolar urea and prostaglandin F2 alpha v dilatation and evacuation. JAMA. 1984;251(7):916-9.
Grimes DA, Schulz KF, Cates W Jr, Tyler CW Jr. Mid-trimester abortion by dilatation and evacuation: a safe and practical alternative. N Engl J Med. 1977;296(20):1141-5.
Hern WM. Serial multiple laminaria and adjunctive urea in late outpatient dilatation and evacuation abortion. Obstet Gynecol. 1984;63:543-9.
Peterson WF, Berry N, Grace MR, Gulbran- son CL. Second-trimester abortion by dilatation and evacuation: an analysis of 11,747 cases. Obstet Gynecol. 1983;62:185-90.
Cowett A, Golub R, Grobman W. Cost-effectiveness of dilation and evacuation versus the induction of labor for second-trimester pregnancy termination. Am J Obstet Gynecol. 2006;194:768-73.
Darney PD, Dorward K. Cervical dilation be- fore first-trimester elective abortion: a controlled comparison of meteneprost, laminaria and hypan. Obstet Gynecol. 1987;70:397-400.
Chen JK, Elder MG. Preoperative cervical dilatation by vaginal pessaries containing prostaglandin E1 analogue. Obstet Gynecol. 1983;62:339-42.
Lauersen HN, Den T, Iliescu C, Wilson KH, Graves ZR. Cervi- cal priming prior to dilatation and evacuation: a comparison of methods. Am J Obstet Gynecol. 1982;14:890-4.
Hammond C. Recent advances in second-trimester abortion: an evidence- based review. Am J Obstet Gynecol. 2009;200:347-56.
Kafrissen ME, Barke MW, Workman P, Schulz KF, Grimes DA. Coagulopathy and induced abortion methods: rates and relative risks. Am J Obstet Gynecol. 1983;147:344-5.
Kapp N, Todd CS, Yadgarova KT, Alibayeva G, Nazarova D, Loza O, et al. A randomized comparison of misoprostol to intra- uterine instillation of hypertonic saline plus a prostaglandin F2 analogue for second trimester induction termination in Uzbekistan. Contraception. 2007;76:461-6.
Peyron R, Aubeny E, Targosz V, Silvestre L, Renault M, Elkik F, et al. Early termination of pregnancy with mifepristone (Ru- 486) and the orally active prostaglandin misoprostol. N Engl J Med. 1993;328:1509-13.
Andersen LF, Poulsen HK, Sorensen SS, Christensen BM, Sponland G, Skjeldestad FE. Termination of 2nd trimester pregnancy with gemeprost vaginal pessaries and intra-amniotic Pgf2-alpha: a comparative study. Eur J Obstet Gynecol Reprod Biol. 1989;311-7.
Cameron IT, Baird DT. The use of 16, 16-dimethyl-trans-delta-2 prostaglandin-E1 methyl-ester (gemeprost) vaginal pessaries for the termination of pregnancy in the early 2nd trimester: a comparison with extra-amniotic prostaglandin-E2. Br J Obstet Gynaecol. 1984;91:1136-40.
Su LL, Biswas A, Choolani M, Kalaichelvan V, Singh K. A prospective, randomized compar- ison of vaginal misoprostol versus intra-amni- otic prostaglandins for midtrimester termination of pregnancy. Am J Obstet Gynecol. 2005;193:1410-4.
Nor Azlin M, Abdullah H, Zainul Rashid M, Jamil M. Misoprostol (alone) in second trimester terminations of pregnancy: as effective as gemeprost? J Obstet Gynaecol. 2006;26:546-9.
Nuutila M, Toivonen J, Ylikorkala O, Halmesmaki AE. A comparison between two doses of intravaginal misoprostol and ge- meprost for induction of second-trimester abortion. Obstet Gynecol. 1997;90:896-900.
Wong KS, Ngai CSW, Wong AYK, Tang LCH, Ho PC. Vaginal misoprostol compared with vaginal gemeprost in termination of second trimester pregnancy: a randomized trial. Contraception. 1998;58:207-10.
Nuthalapaty FS, Ramsey PS, Biggio JR, Owen J. High-dose vaginal misoprostol versus concentrated oxytocin plus low-dose vaginal misoprostol for midtrimester labor induction: a randomized trial. Am J Obstet Gynecol. 2005;193(Suppl1):S1065-70.
Ashok PW, Templeton A, Wagaarachchi PT, Flett GM. Midtrimester Medical Termination of Pregnancy: A Review of 1002 Consecutive Cases. Contraception. 2004;69:51-8.
Dalvie SS. Second Trimester Abortions in India. Reprod Health Matters. 2008;16(31):37-45.
Lakshmi RG, Pranavi B, George N, Saraswathi K. A clinical observational study on second-trimester abortion. Int J Reprod Contracept Obstet Gynecol. 2020;9:1339-45.
Shantikumar U, Bagga R, Kalra J, Jain V, Suri V, Singh A, et al. Second-Trimester Medical Abortion with Misoprostol Preceded by Two Sequential Doses of Mifepristone: An Observational Study. J Obstet Gynaecol India. 2022;72(1):26-35.
Finer LB, Frohwirth LF, Dauphinee LA, Singh S, Moore AM. Timing of steps and reasons for delay in obtaining abortions in the United States. Contraception. 2006;74:334-44.
Lalitkumar S, Bygdeman M, Gemzell-Danielsson K. Second trimester induced abortion: a review. Human Reprod Update. 2007;13(1):37-52.
Grimes DA, Smith MS, Witham AD. Mife-pristone and misoprostol versus dilation and evacuation for midtrimester abortion: a pilot randomized controlled trial. BJOG. 2004;111:148-53.
Ashok PW, Templeton A, Wagaarachchi PT, Flett GM. Midtrimester medical termination of pregnancy: a review of 1002 consecutive cases. Contraception. 2004;69(1):51-8.
Thong KJ, Baird DT. An open study comparing two regimens of gemeprost for the termination of pregnancy in the second trimester. Acta Obstet Gynecol Scand. 1992;71(3):191-6.
Ranjan S, Sarojini A, Mohapatra I, Vivekanand A, Ranjan S. Comparison of intravaginal misoprostol alone and in combination with intracervical Foley’s catheter for termination of second trimester pregnancy-3 years study at a tertiary care hospital. Perspect Med Res. 2016;4:3-8.
